Skip to main content

Animations

MJFF Publications

7321 - 7330 of 8684 Results
Title
Year
  • Year
  • 2022
  • 2025
  • 2024
  • 2008
  • 2023
  • 2023
  • 2025
  • 2018
  • 2016
  • 2006
  • Summary Details
    OPEN
    Title: Identifying and characterising sources of variability in digital outcome measures in Parkinson’s disease
    Journal Name: npj Digital Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41746-022-00643-4
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson’s disease
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.celrep.2025.115355
    Citation Count: 2
  • Summary Details
    OPEN
    Title: A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.jbc.2024.107469
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease
    Journal Name: Journal of Clinical Investigation
    Publisher: American Society for Clinical Investigation
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1172/jci35781
    Citation Count: 195
  • Summary Details
    OPEN
    Title: Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-023-00497-x
    Citation Count: 72
  • Summary Details
    RESTRICTED
    Title: The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.29688
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson’s disease
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2025.115636
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Identification of small molecules that bind to the mitochondrial protein mitoNEET
    Journal Name: Bioorganic & Medicinal Chemistry Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bmcl.2016.09.009
    Citation Count: 36
  • Summary Details
    RESTRICTED
    Title: Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease
    Journal Name: The FASEB Journal
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1096/fj.03-1449com
    Citation Count: 692
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.